← EUPRAXIA PHARMACEUTICALS INC. (EPRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
EUPRAXIA PHARMACEUTICALS INC. (EPRX)
Pharmaceutical Preparations · market cap $427M · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Eupraxia Pharmaceuticals (EPRX) is a small Canadian pharmaceutical company with 33 employees and a ~$434M market cap trading at ~$6.52. Its pipeline centers on EP-104IAR, a locally-delivered steroid formulation in Phase 2 for knee osteoarthritis, and EP-104GI, a Phase 2 asset targeting eosinophilic esophagitis. The next meaningful binary catalyst is Phase 2 data for EP-104GI, estimated around December 15, 2026.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · EP-104GIimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EP-104IAR 25 mg | Phase 2 | Osteoarthritis, Knee |
| EP-104GI | Phase 2 | Eosinophilic Esophagitis |
Price & technical context
3-month
+17.0%
6-month
+6.8%
12-month
+32.7%
52-wk range
$5.33–$9.10
vs 50-day MA
+7.3%
vs 200-day MA
+6.9%
Realized vol
63.6%
Max drawdown
-35.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EPRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.